Phase III Blincyto Study in Leukemia Stopped Very early After Resting OS Key Endpoint
A Set III study of Blincyto satisfied its Key endpoint of total survival in patients along with acute lymphoblastic leukemia adhering to a prespecified acting analysis. The study was stopped early.
The randomized, open-mark TOWER study analyzed the efficacy of Blincyto (blinatumomab) versus the traditional of treatment in adult patients along with Philly chromosome-adverse relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
